Literature DB >> 9103414

Immune deviation in relation to ocular immune privilege.

J W Streilein1, B R Ksander, A W Taylor.   

Abstract

Immune privilege in the eye is a dynamic state in which the immune response to ocular Ags is molded and modified by the eye itself. Immune privilege correlates with systemic alterations in the immune response such that deviant forms of immunity emerge. The eye itself contributes to immune deviation, in part by displaying unique immunoregulatory factors in aqueous humor and expressed on ocular cells. When T cells encounter Ag in the eye, they can become anergic, undergo apoptosis, secrete TGF-beta, and/or release soluble regulatory factors containing the TCR alpha-chain. Ags taken up by indigenous APC escape the eye and reach the spleen where they activate a unique spectrum of Ag-specific T and B cells. The absence of systemic delayed hypersensitivity and complement-fixing Abs in this deviant response probably relates to the fact that inflammation is deleterious to vision and leads to blindness. Immune privilege is the eye's way of protecting its vital function from the ravages of immunopathogenic injury.

Entities:  

Mesh:

Year:  1997        PMID: 9103414

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

2.  Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

Authors:  M Harada; K Tatsugami; M Nomoto; K Nomoto
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  Ipsilateral submandibular lymphadenectomy does not prolong orthotopic corneal graft survival in mice.

Authors:  Felix Schulte; Er-Ping Zhang; Jürgen Franke; Ralf Ignatius; Friedrich Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

4.  Apoptosis of CD4+ T cells occurs in experimental autoimmune anterior uveitis (EAAU).

Authors:  H G Yu; H Chung; W J Lee
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  Retinal laser burn disrupts immune privilege in the eye.

Authors:  Hong Qiao; Kenyatta Lucas; Joan Stein-Streilein
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID).

Authors:  T J D'Orazio; J Y Niederkorn
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

7.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

8.  Rabies virus ocular disease: T-cell-dependent protection is under the control of signaling by the p55 tumor necrosis factor alpha receptor, p55TNFR.

Authors:  S Camelo; J Castellanos; M Lafage; M Lafon
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation.

Authors:  Yalin Ren; Peizeng Yang; Bing Li; Yang Gao; Hongyan Zhou; Xiangkun Huang; Lianxiang Zhu; Aize Kijlstra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

10.  Increased expression of Foxp3 in splenic CD8+ T cells from mice with anterior chamber-associated immune deviation.

Authors:  Liqiong Jiang; Peizeng Yang; Hao He; Bing Li; Xiaomin Lin; Shengping Hou; Hongyan Zhou; Xiangkun Huang; Kijlstra Aize
Journal:  Mol Vis       Date:  2007-06-19       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.